OVID THERAPEUTICS DL-,001 Logo
US6904691010
A2DQ8S
OVID

OVID THERAPEUTICS DL-,001

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 5,67 € (+138,24 %). Medianen er 5,44 € (+128,57 %).

Køb
  11
Behold
  3
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Ovid Therapeutics unveils pipeline strategy for neuronal hyperexcitability and KCC2 platform

    Ovid Therapeutics presented at the H.C. Wainwright conference its focus strategy on brain disorders driven by neuronal hyperexcitability, centered on two lead programs: OV329 for epilepsy and OV4071, the first oral direct KCC2 activator. Management said OV329 shows a strong safety profile and is expected to report photosensitivity data in the coming months and phase II results in about a year; OV4071 is in phase I, a ketamine challenge is planned before year‑end, and a phase II program for acute schizophrenia is scheduled for mid‑2025. Financial figures were not discussed; management emphasized the platform ambitions, biomarker‑driven development and multiple near‑term proof‑of‑concept catalysts. » Mere på de.investing.com


  • Ovid Therapeutics emphasizes KCC2 program and epilepsy pipeline as value drivers

    At the Cantor conference Ovid Therapeutics presented its two‑pillar strategy centered on the KCC2 program (OV4071) and the epilepsy pipeline (notably OV329), and views KCC2 as the main long‑term value driver if early human data confirm preclinical results. OV4071 is in phase I; a ketamine challenge and several biomarker studies are intended to link earlier animal data with human data. OV329 is being positioned to differentiate in focal-onset and pediatric epilepsies; proof‑of‑concept data and a phase II are planned for 2024/2025. Ovid also retains rights to milestone/license payments from Soticlestat, which represents additional upside without development risk. » Mere på de.investing.com


  • Ovid Therapeutics names Kevin Norrett chief business officer, promotes key executives

    Ovid Therapeutics appointed Kevin Norrett as chief business officer to lead business development and strategic partnerships. Charles Carter was promoted to CFO, succeeding Jeffrey Rona who will remain a long-term advisor through 2027, and Victoria Fort was promoted to chief strategy officer. The company reported Q1 EPS of (12c), said development programs are on track, and expects to be well capitalized into 2029. » Mere på finance.yahoo.com


  • Ovid Therapeutics appoints Kevin Norrett as chief business officer and restructures leadership team

    Ovid Therapeutics brings in Kevin Norrett as chief business officer to lead business and corporate development and strategic partnerships. Charles Carter was promoted to chief financial officer; Jeffrey Rona will remain on board as an advisor through 2027. Eliseo Salinas joins as executive R&D advisor and Victoria Fort was promoted to chief strategy officer; Fort led financing rounds that secure the company’s cash runway through 2029. The company is developing, among others, OV329 for treatment-resistant focal-onset seizures and OV4071 for central nervous system disorders. » Mere på de.investing.com


  • Ovid Therapeutics appoints Dr. Anna Greka to board and creates science and technology committee

    Ovid Therapeutics has appointed Dr. Anna Greka to its board effective June 15, 2026; she will chair the newly formed Science and Technology Committee and join the Compensation Committee. Dr. Greka is head of Ladders to Cures, a Core Institute member at the Broad Institute, a professor at Harvard Medical School, and has founded and advised several biotech companies. The announcement comes after the stock rose more than 700% over the past year; Ovid is developing, among other programs, OV329 for treatment-resistant focal onset seizures and additional KCC2 activators. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde OVID THERAPEUTICS DL-,001 en omsætning på 0 € og et nettoresultat på -18,35 mio. €
(EUR) september 2026
YoY
Omsætning 0 100,00 %
Bruttofortjeneste 0 100,00 %
Nettoresultat -18,35 mio. 77,08 %
EBITDA -18,05 mio. 74,42 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
435 mio. €
Antal aktier
188,73 mio.
Højeste/laveste i 52 uger
2,82 € - 1,07 €
Udbytte Nej
Beta
0,24
P/E (PE Ratio)
-6,20
PEG (PEG Ratio)
0,21
K/I (PB Ratio)
2,60
P/S (PS Ratio)
330,38

Virksomhedsprofil

Ovid Therapeutics Inc. er et biofarmaceutisk selskab, der udvikler effektfulde lægemidler til patienter og familier med neurologiske lidelser i USA. Selskabet udvikler OV101, en lægemiddelkandidat, som er i fase 2A kliniske forsøg til behandling af fragilt X-syndrom; OV329, en GABA-aminotransferasehæmmer til behandling af anfald forbundet med tuberøs sklerose-kompleks og infantile spasmer; og OV350, et småmolekyle til behandling af epilepsi. Selskabet udvikler også OV882, en short hairpin RNA-genterapi til behandling af Angelman-syndrom; og OV815 til behandling af neurologiske lidelser forbundet med kinesin-familien af proteiner. Selskabet har licens- og samarbejdsaftaler med Healx, AstraZeneca AB, H. Lundbeck A/S og Northwestern University samt Marinus Pharmaceuticals, Inc. Selskabet blev stiftet i 2014 og har hovedkvarter i New York, New York.

Navn
OVID THERAPEUTICS DL-,001
CEO
Margaret Alexander
Hjemsted New York City, ny
USA
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
05.05.2017
Medarbejdere 23

Tickersymboler

Børs Symbol
NASDAQ
OVID
Frankfurt
1OT.F
Düsseldorf
1OT.DU
München
1OT.MU
🍪

Parqet  bruger cookies. Læs mere